Efficient targeting of heart lesions with cardiac myofibroblasts: Combined gene and cell therapy enhanced by magnetic steering

Maximilian Schiffer, Katrin Wagner, E. Carls, Julia Nicke, Michael Hesse, Raluca M. Fratila, Staffan Hildebrand, Alexander Pfeifer, Dietmar Eberbeck, Mohsen Mohammadi, José de la Fuente, Bernd K. Fleischmann, Wilhelm RoellbioRxiv 2024 · DOI

TL;DR

This paper presents a novel strategy for treating cardiac scars by combining gene therapy with magnetic steering of cardiac myofibroblasts (mFB). This approach significantly improves cell engraftment in damaged heart tissue and, when combined with Cx43 gene therapy, effectively reduces life-threatening arrhythmias.

What Problem Does This Paper Address?

The aftermath of a heart attack often leaves behind a cardiac scar, a dense collagenous tissue populated by myofibroblasts. This scar tissue is notoriously difficult to treat and can lead to serious complications like ventricular tachycardia (VT), a potentially fatal heart rhythm. Current therapeutic strategies for scar management are limited, and attempts to deliver therapeutic genes or cells directly to the scar have faced challenges with low efficiency and poor cell survival. This paper aims to overcome these limitations by developing a method to efficiently deliver genetically modified cardiac myofibroblasts to the scar tissue, thereby improving its function and reducing the risk of arrhythmias.

Methods

The researchers employed a multi-pronged approach:

  • Cell Isolation and Expansion: Embryonic cardiac myofibroblasts (mFB) were isolated from mouse hearts and expanded in vitro. This provided a readily available source of cells for therapeutic use.
  • Genetic Modification: mFB were genetically engineered using lentiviral vectors (LV) to overexpress Connexin43 (Cx43), a protein crucial for cell-to-cell communication in the heart.
  • Magnetic Nanoparticle (MNP) Loading: The genetically modified mFB were loaded with specific magnetic nanoparticles (PMAO-MNP). These nanoparticles serve two purposes: enabling tracking of the cells and facilitating magnetic steering.
  • Magnetic Steering: During injection into the infarcted heart, an external magnet was used to guide the MNP-loaded mFB to the target scar tissue, significantly enhancing their retention and engraftment.
  • In Vivo Assessment: The efficacy of this approach was evaluated through various techniques, including:
  • Histomorphological Analysis: To visualize and quantify engrafted cells and scar tissue.
  • Immunofluorescence Staining: To identify specific cell types and protein expression (e.g., Cx43, Vimentin, Ki67).
  • Western Blotting and qPCR: To assess protein and gene expression levels.
  • Electrophysiology Testing: To measure cardiac electrical activity and assess the incidence of VT.
  • Echocardiography: To evaluate cardiac function (e.g., fractional shortening, wall thickening).

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Myofibroblasts as Therapeutic Cells: The study highlights cardiac myofibroblasts as promising candidates for cardiac repair due to their resilience in the harsh environment of a cardiac scar and their proliferative capacity.
  • PMAO-MNP Superiority: PMAO-MNP were identified as the optimal magnetic nanoparticles due to their low toxicity, high magnetic retention, and lack of intracellular aggregation, making them ideal for cell delivery.
  • Magnetic Steering is Key: The use of magnetic steering dramatically improved the engraftment of mFB in the cardiac scar, a critical step for therapeutic success.
  • Cx43 Overexpression for Anti-Arrhythmic Effects: Overexpressing Cx43 in mFB not only enhanced their integration but also conferred significant protection against post-infarct VT, suggesting a role in improving electrical coupling within the scar.
  • Synergistic Effect of Gene and Cell Therapy: The combination of ex vivo gene therapy (Cx43 overexpression) and in vivo cell therapy (magnetically guided mFB delivery) proved to be a powerful strategy for both scar repair and functional improvement.

Key Results

  • Enhanced Engraftment: Magnetic steering of MNP-loaded mFB resulted in approximately a 4-fold increase in engrafted cells compared to previous methods.
  • Improved Endogenous Cell Activity: Grafted mFB enhanced the proliferation of endogenous myofibroblasts (endoFB) by approximately 4-fold.
  • Reduced VT Incidence: Mice treated with Cx43-overexpressing mFB showed a significant reduction in VT incidence by approximately 50% at both two and eight weeks post-injection.
  • Improved Cardiac Function: Echocardiography revealed improved cardiac pump function and anterior wall thickening in mice treated with Cx43-overexpressing mFB.
  • Long-Term Engraftment: Engrafted mFB were detected in the scar area even at 8 weeks post-surgery, indicating successful long-term integration.

Limitations and Future Work

  • Cell Loss Over Time: While engraftment was significant, the number of grafted cells decreased over time. The authors suspect immune-based cell rejection or normal cell loss as potential causes.
  • Mechanism of Endogenous Cell Proliferation: The study observed that grafted exoFB enhanced the proliferation of endogenous endoFB, but the exact signaling mechanism remains to be fully elucidated.
  • Autologous vs. Embryonic Cells: The study used embryonic mFB. Future work could explore whether autologous cells or cells derived from induced pluripotent stem cells (hiPSCs) would offer advantages in terms of engraftment and immune response.
  • Large Animal Models: The authors suggest that future research should investigate the efficacy of this approach in larger animal models to assess its translational potential.
  • Modulating Immune Response: The strategy could be further developed to modify the immune response in the scar by overexpressing immunomodulating factors or other target genes in mFB.

Summary updated

Abstract

1 Abstract The cardiac scar is a collagen-rich area, which is populated by myofibroblasts and has proven little amenable for therapeutic interventions. Herein, we have established an efficient targeting strategy for cardiac lesions by genetically manipulating embryonic cardiac myofibroblasts (mFB) in vitro , load the cells with magnetic nanoparticles and inject these into infarcted mouse hearts using magnetic steering. This yields strongly increased numbers (∼4 fold compared to other cell types) of engrafted mFB. The injected mFB and endogenous myofibroblast (endoFB) population remain separate in the scar, but grafted mFB enhance the proliferation rate of endoFB by ∼4 fold. We also tested the functional impact of this approach by grafting lentiviral (LV)-transduced Connexin43 (Cx43) overexpressing mFB into the cardiac lesion. Prominent engraftment of Cx43 + mFB provides strong protection against post-infarct ventricular tachycardia (VT) in vivo , as VT incidence is reduced by ∼50 % at two and eight weeks after cell injection. Thus, ex vivo gene and subsequent in vivo cell therapy combined with magnetic steering of cardiac mFB enable efficient functional targeting of the cardiac scar.
BibTeX
@misc{schiffer2024efficient,
  author = {Maximilian Schiffer and Katrin Wagner and E. Carls and Julia Nicke and Michael Hesse and Raluca M. Fratila and Staffan Hildebrand and Alexander Pfeifer and Dietmar Eberbeck and Mohsen Mohammadi and José de la Fuente and Bernd K. Fleischmann and Wilhelm Roell},
  title = {{Efficient targeting of heart lesions with cardiac myofibroblasts: Combined gene and cell therapy enhanced by magnetic steering}},
  year = {2024},
  doi = {10.1101/2024.02.16.580672},
  howpublished = {bioRxiv},
}

Loading related content...

Figure